Memantine

3,5-Dimethyl-1-aminoadamantane

Namenda, Ebixa, Axura, Memaxa, Namenda XR

Psychoactive Class

Chemical Class

Memantine is an adamantane derivative and NMDA receptor antagonist primarily prescribed for the management of moderate-to-severe Alzheimer's disease.¹ It works by blocking glutamate-mediated neuronal excitotoxicity, distinguishing it mechanistically from the cholinesterase inhibitors typically used in Alzheimer's treatment.²³ At supratherapeutic doses, memantine can produce prolonged dissociative effects reportedly lasting 16 or more hours, placing it among the longest-duration dissociatives available.

Dosage & Duration

Dosage

Threshold~10 mg

Light10-20 mg

Moderate20-40 mg

Heavy40+ mg

Bioavailability

~100%

Duration

Onset30-90 minutes

After Effects1-72 hours

Total12-72 hours

Half-life

60–80 hours

Subjective Effects

Memantine is an NMDA receptor antagonist whose subjective profile is fundamentally dissociative, though its character is far removed from faster-acting dissociatives. Even therapeutic doses have been found to produce mild dissociative-like effects, while supratherapeutic doses can bring on a prolonged dissociative 'hole' lasting up to 16 or more hours. Notably, it appears to lack the euphoria associated with many recreational substances, and its extremely long duration makes recreational use uncommon.

Physical

The body experience is dominated by CNS depression, including dizziness, drowsiness, sedation, lethargy, and slurred speech, with heavier exposures capable of progressing to loss of consciousness.

Sedation

Cognitive

The headspace is marked by dissociation, confusion, and disorientation, sometimes accompanied by anxiety or agitation. Because NMDA antagonism interferes with the synaptic plasticity underlying learning and memory, higher doses can impair memory formation.

Disorienting

Anxiety

Visual

Hallucinatory States

Reported in a subset of users rather than as a consistent effect.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Memantine acts as an uncompetitive antagonist of the NMDA receptor, binding within the open ion channel to block pathological calcium influx driven by excessive glutamate signaling.⁴ It displays preferential inhibition of extrasynaptic NMDA receptors, while its low affinity and rapid off-rate kinetics allow normal synaptic NMDA function to be preserved during physiological glutamate release.⁵⁶ Beyond its primary mechanism, memantine acts as a non-competitive antagonist at 5-HT3 receptors with potency similar to its NMDA activity⁴ and as an antagonist at α7 nicotinic acetylcholine receptors.⁶ It has additionally been reported to act as an agonist at dopamine D2High receptors⁷ and as a weak agonist at sigma-1 receptors.

Pharmacokinetics

Memantine has an oral bioavailability of approximately 100%⁸ and reaches peak plasma levels within 3 to 7 hours.⁴ It undergoes negligible metabolism by cytochrome P450 enzymes,⁴ producing three minor metabolites that retain minimal NMDA receptor antagonist activity.⁴ The drug is eliminated primarily through renal excretion, with 57 to 82% appearing unchanged in urine.⁹ Its elimination half-life ranges from 60 to 80 hours,⁴ and renal clearance is dependent on urinary pH, with more alkaline urine slowing elimination.⁴

Interactions

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AbacavirAbrocitinibAcebutololAceclofenacAcemetacin

TripSit

Tolerance

Cross Tolerance

Other NMDA receptor antagonists

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Recreational use is rare due to the drug's very long duration of action (>40 hours) and apparent lack of euphoric effects. Misuse potential is considered limited compared to other NMDA receptor antagonists.¹⁰

Toxicity

Cardiovascular

Blood clots and heart failure have been reported as severe but rare adverse effects, primarily documented in clinical use among elderly patients with dementia.⁸

Urinary System

Cystitis has been reported as a less common adverse effect in clinical settings.

Psychosis Risk

Psychosis is listed as a severe but rare side effect.⁸ Hallucinations and confusion are more common adverse effects (≥1% of patients) in clinical populations.¹ At supratherapeutic recreational doses, dissociative effects may produce psychotomimetic symptoms.

History & Culture

Discovery and Development

Memantine was first synthesized and patented by Eli Lilly and Company in 1963, originally developed as a potential anti-diabetic agent.¹¹ However, the compound proved ineffective at lowering blood sugar and the project stalled. Nearly a decade later, in 1972, researchers…

Trip Reports

Legality

By Country

United StatesPrescription medication (Rx-only)

FDA-approved in 2013 for the management of Alzheimer's disease. Not a scheduled controlled substance under the Controlled Substances Act.¹ Available only by prescription; generic and brand name formulations are marketed.¹

European UnionPrescription medication

Approved and marketed as a prescription pharmaceutical across EU member states.¹⁴²⁰ Brand name products including Axura have been available since at least 2016.

CanadaPrescription medication

Approved pharmaceutical available by prescription.¹⁹ Generic and brand name formulations have been marketed since at least 2010, including products from multiple labellers.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Memantine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Memantine

3,5-Dimethyl-1-aminoadamantane

Namenda, Ebixa, Axura, Memaxa, Namenda XR

Psychoactive Class

Dissociative Nootropic

Chemical Class

Adamantane derivative